MedTrace Logo

Qvar vs FP in Pediatrics

NCT01877954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2654

Last updated 2013-06-14

No results posted yet for this study

Summary

The primary aim of this study was to compare the absolute and relative effectiveness of asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS) maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI.

Conditions

Interventions

DRUG

Extra-fine hydrofluoroalkane beclometasone dipropionate

DRUG

Fluticasone propionate

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price · Research in real life

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01877954 on ClinicalTrials.gov